Results 151 to 160 of about 937 (188)

Asfotase-alfa

Reactions Weekly, 2021
openaire   +1 more source

Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review

Bone
Hypophosphatasia (HPP) is a rare genetic disorder characterized by defective bone mineralization, leading to skeletal abnormalities and systemic complications. Asfotase alfa, a recombinant human tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy, has emerged as a promising treatment for HPP.
Amirhossein Shirinezhad, Sina Esmaeili, Alireza Azarboo, Yasaman Tavakoli, Amir Human Hoveidaei, Negar Zareshahi, Amirhossein Ghaseminejad-Raeini   +6 more
openaire   +2 more sources

Asfotase-alfa

Reactions Weekly, 2017
openaire   +2 more sources

Asfotase-alfa/influenza-virus-vaccine

Reactions Weekly, 2023
openaire   +1 more source

Asfotase alfa

Reactions Weekly, 2019
openaire   +1 more source

M064 NON-IRRITANT CONCENTRATIONS FOR ASFOTASE ALFA SKIN TESTING

Annals of Allergy, Asthma & Immunology, 2019
A. Mechtler, I. Carrillo-Martin, K. Wierenga, A. Gonzalez-Estrada   +3 more
openaire   +1 more source

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Lancet, The, 2023
exaly  

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Lancet, The, 2007
Alain Ravaud, Sergio Bracarda, C?zary A Szczylik   +2 more
exaly  

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Lancet, The, 2005
Harry La Janssen, Yilmaz Cakaloglu, Guido Gerken   +2 more
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly